RHYTHM PHARMACEUTICALS, INC. Deferred Income Tax Expense (Benefit)
RHYTHM PHARMACEUTICALS, INC. (RYTM) reported Deferred Income Tax Expense (Benefit) of $0 for the 12-month period ending 2025-12-31, per its 10-K filed 2026-02-26.
Financial Statements › Cash Flow › Operating Activities
us-gaap:DeferredIncomeTaxExpenseBenefit · last filed 2026-02-26
- RHYTHM PHARMACEUTICALS, INC. deferred income tax expense (benefit) for the quarter ending 2021-09-30 was -$8.99M.
- RHYTHM PHARMACEUTICALS, INC. deferred income tax expense (benefit) for the quarter ending 2021-06-30 was -$5.02M.
- RHYTHM PHARMACEUTICALS, INC. deferred income tax expense (benefit) for the quarter ending 2021-03-31 was $22.01M.
- RHYTHM PHARMACEUTICALS, INC. deferred income tax expense (benefit) for fiscal 2025 was $0.00.
- RHYTHM PHARMACEUTICALS, INC. deferred income tax expense (benefit) for fiscal 2024 was $0.00.
- RHYTHM PHARMACEUTICALS, INC. deferred income tax expense (benefit) for fiscal 2023 was $0.00.
| Period end | Deferred Income Tax Expense (Benefit) 3 month | Deferred Income Tax Expense (Benefit) 6 month | Deferred Income Tax Expense (Benefit) 9 month | Deferred Income Tax Expense (Benefit) 12 month |
|---|---|---|---|---|
| 2025-12-31 | $0.00 10-K · filed 2026-02-26 | |||
| 2024-12-31 | $0.00 10-K · filed 2026-02-26 | |||
| 2023-12-31 | $0.00 10-K · filed 2026-02-26 | |||
| 2021-09-30 | -$8.99M derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-08 | -$14.02M derived: sum of 2 quarters · filed 2022-11-08 | $7.99M 10-Q · filed 2022-11-08 | |
| 2021-06-30 | -$5.02M derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-03 | $16.98M 10-Q · filed 2022-08-03 | ||
| 2021-03-31 | $22.01M 10-Q · filed 2022-05-03 | |||
| 2018-12-31 | $0.00 10-Q · filed 2019-11-01 | |||
| 2017-12-31 | $0.00 10-Q · filed 2018-11-09 | |||
| 2016-12-31 | $0.00 10-Q · filed 2017-11-14 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Alkermes plc. (ALKS) | $6.844B | 132.74 | |
| Liquidia Corp (LQDA) | United States | $6.347B | 51.23 |
| Amneal Pharmaceuticals, Inc. (AMRX) | $6.326B | 25.62 | |
| IONIS PHARMACEUTICALS INC (IONS) | United States | $7.277B | -23.25 |
| Spyre Therapeutics, Inc. (SYRE) | United States | $7.685B | -43.69 |
| Structure Therapeutics Inc. (GPCR) | United States | $7.710B | -53.41 |
| Mirum Pharmaceuticals, Inc. (MIRM) | United States | $5.798B | -8.81 |
| Travere Therapeutics, Inc. (TVTX) | United States | $5.712B | -123.10 |
| Oruka Therapeutics, Inc. (ORKA) | United States | $5.663B | -43.76 |
| Praxis Precision Medicines, Inc. (PRAX) | United States | $7.884B | -27.60 |